A 32-year-old man with a 5-year history of schizophrenia presents to the psychiatry clinic for follow-up. He has been stable on haloperidol 10 mg daily for the past 3 years with good symptom control. On examination, he is noted to have a resting tremor, rigidity, and bradykinesia. His gait is slow and shuffling. He reports difficulty with fine motor tasks and occasional drooling. What is the most appropriate next step in management?

Explanation

## Clinical Presentation Analysis The patient exhibits classic **extrapyramidal side effects (EPS)** — specifically **parkinsonism** — characterized by the triad of: - Resting tremor - Rigidity - Bradykinesia Additional features include postural abnormalities (shuffling gait) and impaired fine motor control. ## Pathophysiology **Key Point:** First-generation antipsychotics (FGAs) like haloperidol block dopamine D~2~ receptors in the basal ganglia, disrupting the balance between dopaminergic and cholinergic activity. This leads to parkinsonism, particularly in long-term use. ## Management Strategy ### Why Switch Rather Than Add Anticholinergic? While benztropine can temporarily relieve EPS symptoms, the patient has been on haloperidol for 3 years with progressive motor complications. Continuing a high-risk FGA perpetuates the underlying mechanism. **High-Yield:** Second-generation antipsychotics (SGAs) have: - Lower D~2~ receptor occupancy in basal ganglia - Faster dissociation from D~2~ receptors - Lower incidence of parkinsonism (1–2% vs. 20–30% with FGAs) ### Recommended Switch Risperidone or olanzapine are appropriate choices because: 1. They maintain antipsychotic efficacy 2. They have a lower EPS liability than haloperidol 3. The patient's psychotic symptoms are already controlled, so efficacy is not a concern **Clinical Pearl:** Gradual cross-titration (overlap period of 1–2 weeks) is recommended to prevent relapse while minimizing withdrawal effects. ## Why Not Other Options? | Option | Problem | |--------|----------| | Continue + benztropine | Addresses symptom but perpetuates underlying dopamine blockade; anticholinergics carry their own risks (cognitive, urinary retention) | | Reduce dose + beta-blocker | Beta-blockers do not treat parkinsonism; dose reduction may compromise psychotic symptom control | | Discontinue + clozapine monotherapy | Abrupt discontinuation risks relapse; clozapine is reserved for treatment-resistant cases and carries agranulocytosis risk | ## Summary **Mnemonic: SWITCH FGA → SGA = SAFER MOTOR** - **S**witch from FGA - **A**void prolonged EPS risk - **F**avor SGA (lower basal ganglia D~2~ occupancy) - **E**fficacy maintained - **R**educe motor complications